BioMark Diagnostics Financials

BioMark Diagnostics Stock Summary

BioMark Diagnostics competes with Neuronetics, Intelligent Bio, Biodesix, Precipio, and ProPhase Labs. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.

BioMark Diagnostics Key Financial Ratios

There are many critical financial ratios that BioMark Diagnostics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that BioMark Diagnostics reports annually and quarterly.

BioMark Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining BioMark Diagnostics's current stock value. Our valuation model uses many indicators to compare BioMark Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioMark Diagnostics competition to find correlations between indicators driving BioMark Diagnostics's intrinsic value. More Info.BioMark Diagnostics is number one stock in return on asset category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioMark Diagnostics' earnings, one of the primary drivers of an investment's value.

BioMark Diagnostics Systematic Risk

Along with financial statement analysis, the daily predictive indicators of BioMark Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioMark Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioMark Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing BioMark Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioMark Diagnostics's daily price indicators and compare them against related drivers.

When running BioMark Diagnostics' price analysis, check to measure BioMark Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMark Diagnostics is operating at the current time. Most of BioMark Diagnostics' value examination focuses on studying past and present price action to predict the probability of BioMark Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMark Diagnostics' price. Additionally, you may evaluate how the addition of BioMark Diagnostics to your portfolios can decrease your overall portfolio volatility.